Mariam Jamal-Hanjani
Mariam Jamal-Hanjani
UCL Cancer Institute
Verified email at
Cited by
Cited by
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
Tracking the evolution of non–small-cell lung cancer
M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...
New England Journal of Medicine 376 (22), 2109-2121, 2017
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
EC de Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ...
Science 346 (6206), 251-256, 2014
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...
Nature 545 (7655), 446-451, 2017
Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
Cell 171 (6), 1259-1271. e11, 2017
Translational implications of tumor heterogeneity
M Jamal-Hanjani, SA Quezada, J Larkin, C Swanton
Clinical cancer research 21 (6), 1258-1266, 2015
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ...
Cell 173 (3), 581-594. e12, 2018
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ...
Cell 173 (3), 595-610. e11, 2018
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study
M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, ...
PLoS Biol 12 (7), e1001906, 2014
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
Neoantigen-directed immune escape in lung cancer evolution
R Rosenthal, EL Cadieux, R Salgado, M Al Bakir, DA Moore, CT Hiley, ...
Nature 567 (7749), 479-485, 2019
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor–mutant non–small cell lung cancer metastatic to the brain
M Jamal-Hanjani, J Spicer
Clinical Cancer Research 18 (4), 938-944, 2012
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
M Jamal-Hanjani, GA Wilson, S Horswell, R Mitter, O Sakarya, ...
Annals of Oncology 27 (5), 862-867, 2016
Nervous system regionalization entails axial allocation before neural differentiation
V Metzis, S Steinhauser, E Pakanavicius, M Gouti, D Stamataki, ...
Cell 175 (4), 1105-1118. e17, 2018
An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor
N Murugaesu, M Iravani, A Van Weverwijk, A Ivetic, DA Johnson, ...
Cancer discovery 4 (3), 304-317, 2014
Implications of intratumour heterogeneity for treatment stratification
A Crockford, M Jamal‐Hanjani, J Hicks, C Swanton
The Journal of pathology 232 (2), 264-273, 2014
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers
CF Houlihan, N Vora, T Byrne, D Lewer, G Kelly, J Heaney, S Gandhi, ...
The Lancet 396 (10246), e6-e7, 2020
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial
M Jamal-Hanjani, R A'hern, NJ Birkbak, P Gorman, E Grönroos, S Ngang, ...
Annals of Oncology 26 (7), 1340-1346, 2015
Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer
A Guppy, M Jamal-Hanjani, L Pickering
Future Oncology 7 (6), 727-736, 2011
The system can't perform the operation now. Try again later.
Articles 1–20